TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19180358
Drug: Trehalose/Fructose combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trehalose/Fructose combination
Study: 17192336
Drug: C-peptide 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-peptide 1.5 mg/day (divided into four subcutaneous doses) for 6 months
Study: 17192336
Drug: C-peptide 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-peptide 4.5 mg/day for 6 months
Study: 17192336
Drug: C-peptide treatment
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-peptide treatment
Study: 7945477
Drug: Cyclosporine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (5 mg/kg/day)
Study: 6127968
Drug: Diazepam 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 0.15 mg/kg
Study: 11682416
Drug: Meperidine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine 0.5 mg/kg
Study: 29723220
Drug: Cognitive dysfunction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive dysfunction in SLE patients with positive IgG anticardiolipin antibodies (50%) compared to normal cognitive function (18%), P = 0.009
Study: 29723220
Drug: CCL2 levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCL2 levels in CSF of SLE patients with cognitive dysfunction [886.1 (374.9–1439.7) pg/mL] compared to normal cognitive function [515.8 (3.2–1958.2) pg/mL], P = 0.04
Study: 28870217
Drug: MPA (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPA (10 mg) administered daily from early follicular phase
Study: 26216383
Drug: Tocilizumab 8
Normalized name: tocilizumab 80 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab 8 mg/kg i.v. q4 weeks during the first three cycles of carboplatin (AUC5) plus doxorubicin (PLD 30 mg/m2 or doxorubicin 50 mg/m2 i.v., day 1, q4 weeks, for six cycles)
Study: 26216383
Drug: Tocilizumab 8
Normalized name: tocilizumab 80 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab 8 mg/kg i.v. q4 weeks
Study: 22218118
Drug: Losartan, 25
Normalized name: Hydrochlorothiazide-Losartan, 25 mg-100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan, 25 mg, twice per day
Study: 22218118
Drug: Losartan +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan + N-acetyl cysteine (NAC), 600 mg twice daily
Study: 964138
Drug: BCG vaccine
Normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG vaccine (Kopenhagen strain) at 160.000 organisms per dose
Study: 964138
Drug: BCG vaccine
Normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG vaccine (Kopenhagen strain) at lower concentrations (22.000, 50.000, 110.000 organisms per dose)
Study: 29468715
Drug: AZD9977 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9977 (5 to 1200 mg)
Study: 29468715
Drug: AZD9977/eplerenone combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9977/eplerenone combination
Study: 26827266
Drug: Rufinamide therapy
Normalized name: Rufinamide
DrugBank: Rufinamide (DB06201)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rufinamide therapy
Study: 20357504
Drug: N. sativa
Approvals — FDA: no, EMA: no, PMDA: no
Description: N. sativa seed supplementation (2 g/day orally) for 30 days
Study: 20357504
Drug: Placebo (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.1 ml saline solution subcutaneously once a week)
Study: 28589947
Drug: EGCG+RES (epigallocatechin‐3‐gallate
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGCG+RES (epigallocatechin‐3‐gallate and resveratrol, 282 and 80 mg/day, respectively)
Study: 21103659
Drug: Enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg and placebo (n=68)
Study: 21103659
Drug: Enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg and aspirin 100 mg (n=63)
Study: 21103659
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg (n=76)
Study: 19033877
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream (cutaneous anesthesia) applied to the lower leg
Study: 17939194
Drug: Vegetotropic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vegetotropic therapy (Propranolol, Metoclopramid, Atropine)
Study: 2688937
Drug: Artemisinin suppositories
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin suppositories (2800 mg for 3 days)
Study: 1287904
Drug: Artemisinin suppositories
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin suppositories
Study: 21600005
Drug: Multiple micronutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple micronutrient supplement (MMS) at two times the recommended dietary allowance (RDA)
Study: 21600005
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care supplement of 6 multivitamins (MV)
Study: 9249883
Drug: Bolus administration
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus administration of furosemide (twice daily)
Study: 9249883
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of furosemide (over 24 hours)
Study: 9249883
Drug: Bolus administration
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus administration of furosemide
Study: 8491934
Drug: Antimicrobial treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial treatment (amoxicillin, amoxicillin clavulanate potassium, or trimethoprim‐sulfamethoxazole)
Study: 8491934
Drug: No antimicrobial
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antimicrobial medication
Study: 3306809
Drug: Heat treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat treatment combined with radiation
Study: 27255874
Drug: S.A.L.T. device
Approvals — FDA: no, EMA: no, PMDA: no
Description: S.A.L.T. device
Study: 24825135
Drug: Praziquantel 3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel 3% ointment
Study: 23586728
Drug: Mirabegron 100
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirabegron 100 mg once daily for 56 days
Study: 23586728
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for 56 days
Study: 28120446
Drug: Mirabegron 100
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirabegron 100 mg
Study: 17889580
Drug: Erdosteine 600
Normalized name: erdosteine
DrugBank: Erdosteine (DB05057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erdosteine 600 mg daily for 10 days
Study: 17277852
Drug: Early steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early steroid withdrawal with tacrolimus (FK) and mycophenolate mofetil (MMF)
Study: 17277852
Drug: Standard immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard immunosuppressive therapy with steroids, cyclosporine and azathioprine or steroids, FK and MMF (Control Group B)
Study: 9001824
Drug: Broncho-Vaxom (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broncho-Vaxom (one capsule daily, 10 days per month, for 3 consecutive months)
Study: 1355099
Drug: Retinoic acid
Normalized name: Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Retinoic acid (0.1% cream) applied topically for 4 days
Study: 1355099
Drug: Vehicle treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle treatment applied topically for 4 days
Study: 26979631
Drug: Single-nucleotide polymorphisms
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-nucleotide polymorphisms related to matrix metalloproteinase-2 (MMP2), tissue inhibitor of matrix metalloproteinase-2 (TIMP2), and interleukin 16 (IL16)
Study: 26979631
Drug: Single-nucleotide polymorphisms
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-nucleotide polymorphisms related to MMP2, matrix metalloproteinase-1 (MMP1), and leukemia inhibitory factor receptor antisense RNA 1 (LIFR-AS1)
Study: 20191574
Drug: Pharmacologic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic and psychosocial treatment
Study: 20191574
Drug: New medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: New medications
Study: 16084150
Drug: Tezosentan (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezosentan (5 mg/h for 30 minutes, then 1 mg/h for 24-72 hours)
Study: 12612363
Drug: Smoke-free Kids
Normalized name: Mederma for Kids
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Smoke-free Kids programme (adequate treatment with at least three of five core modules)
Study: 12612363
Drug: Smoke-free Kids
Normalized name: Mederma for Kids
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Smoke-free Kids programme (adequate treatment)
Study: 12612363
Drug: Smoke-free Kids
Normalized name: Mederma for Kids
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Smoke-free Kids programme (all parents randomised to treatment)
Study: 7195247
Drug: 1 x
Normalized name: Black Cohosh 1 X Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 20 mg/kg, 2 x 20 mg/kg, or 3 x 20 mg/kg (phase II A trial)
Study: 7195247
Drug: 1 x
Normalized name: Black Cohosh 1 X Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 30 mg/kg (n=53), 1 x 40 mg/kg (n=45), 2 x 20 mg/kg (n=53) (phase II B trial)
Study: 7195247
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 50 mg/kg (phase II A trial)
Study: 7195247
Drug: Three oral
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three oral doses of 20 mg/kg given at 4-h intervals (phase II A trial)
Study: 7195247
Drug: 1 x
Normalized name: Black Cohosh 1 X Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 40 mg/kg (phase II B trial)
Study: 17498487
Drug: General Western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: General Western medicine therapy and differential treatment of traditional Chinese medicine (TCM) based on stage classification
Study: 17498487
Drug: General Western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: General Western medicine and placebo of traditional Chinese herbal medicine
Study: 17498487
Drug: ADL (Activity
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADL (Activity of daily living) scale
Study: 12774471
Drug: Glimepiride (Amaril)
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glimepiride (Amaril) combined with metformin, insulin, repaglynide, and nateglynide
Study: 7775504
Drug: Morphine unit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine unit (moderate to high doses of morphine)
Study: 7775504
Drug: No-morphine unit
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-morphine unit (no morphine or morphine derivatives)
Study: 2107240
Drug: Terfenadine, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine, 1 mg/kg (mean dose, 69.6 ± 11.2 mg)
Study: 2107240
Drug: Chlorpheniramine, 0.12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine, 0.12 mg/kg (mean dose, 8.4 ± 1.3 mg)
Study: 6777801
Drug: Ethanol at
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol at 0.76 ml kg‐1 (orally)
Study: 6777801
Drug: Ethanol at
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol at 0.15 ml kg‐1
Study: 26353009
Drug: Metyrapone monotherapy
Normalized name: Metyrapone
DrugBank: Metyrapone (DB01011)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metyrapone monotherapy
Study: 25177431
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of steroid and Korean red ginseng (KRG)
Study: 25177431
Drug: KRG as
Approvals — FDA: no, EMA: no, PMDA: no
Description: KRG as an adjuvant to steroid therapy
Study: 19523608
Drug: Live oral
Normalized name: Cholera Vaccine Live Oral
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live oral cholera vaccine VA1.3 (5 x 10(9) CFU)
Study: 17530295
Drug: Probiotics (Lactobacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (Lactobacillus acidophilus 10(8) CFU/g 1 g b.i.d.)
Study: 17530295
Drug: Antibiotics (trimethoprim/sulfamethoxazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (trimethoprim/sulfamethoxazole 2/10 mg/kg h.s.)
Study: 1922220
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of aspirin
Study: 15026612
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of aspirin
Study: 15026612
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg of aspirin
Study: 19211442
Drug: 325 mg
Normalized name: lysine 325 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 325 mg of aspirin
Study: 15026612
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of aspirin (AIS subgroup)
Study: 8993489
Drug: Tacrine (80,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrine (80, 120, or 160 mg/day)
Study: 8226485
Drug: Caffeine (CAF)
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine (CAF) 5 mg/kg
Study: 23302821
Drug: Acupressure treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupressure treatment (9-minute daily for 4 weeks)
Study: 19034054
Drug: Combined vaginal
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Combined vaginal and oral low‐dose estrogen plus progestogen therapy (EPT)
Study: 17452842
Drug: Liposomal melanin
Normalized name: melanin synthetic (tyrosine, peroxide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal melanin spray (Lipoxome) with 3 cycles of 800 nm diode laser at intervals of 8 weeks (28-40 J/cm)
Study: 17452842
Drug: Physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological saline spray before diode laser treatment
Study: 15050312
Drug: Amifostine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amifostine (500 mg i.v. 20‐30 min before treatment the first 2 days of each week)
Study: 15050312
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (thoracic RT plus oral etoposide and cisplatin without amifostine)
Study: 17196507
Drug: 1 mg/day
Normalized name: Lyllana 0.1 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/day finasteride
Study: 2145236
Drug: Enoximone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone (1 mg/kg bolus, every 8 hours for 48 hours)
Study: 2145236
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (frusemide, nitrates, dopamine‐dobutamine)
Study: 438356
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg loperamide HCl (syrup formulation)
Study: 438356
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg loperamide HCl (capsule formulation)
Study: 438356
Drug: Comparative analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparative analysis of syrup and capsule formulations
Study: 438356
Drug: Excretion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Excretion of unchanged loperamide
Study: 30267699
Drug: Fluorometholone 0.1%
Normalized name: FLUOROMETHOLONE 0.1% OINT,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorometholone 0.1% twice daily for 4 weeks
Study: 30267699
Drug: Fluorometholone 0.1%
Normalized name: FLUOROMETHOLONE 0.1% OINT,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorometholone 0.1% four times daily for 4 weeks
Study: 30267699
Drug: Fluorometholone 0.1%
Normalized name: FLUOROMETHOLONE 0.1% OINT,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorometholone 0.1% four times daily for 8 weeks
Study: 28853994
Drug: Whole red
Normalized name: red mulberry whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole red grape juice (150 ml for men and 100 ml for women)
Study: 25955226
Drug: PTH (1-84)
Normalized name: PTH
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PTH (1-84) 100 μg/d
Study: 21856809
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (2-g loading dose followed by 500 mg every 12 hours)
Study: 15114031
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin therapy (RPL-IVIg); 500 mg IVIg/kg/month
Study: 4940157
Drug: Immunotherapy (B.C.G.)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (B.C.G.)
Study: 12628840
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment
Study: 31332110
Drug: Single-pass technique
Normalized name: MED PASS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-pass technique for lenticule preparation
Study: 31332110
Drug: Double-pass technique
Normalized name: MED PASS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-pass technique for lenticule preparation
Study: 26102258
Drug: Medicine Ball
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicine Ball Training (MBT)
Study: 27541380
Drug: Rosuvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (20 mg/day)
Study: 22967451
Drug: EC-T (epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: EC-T (epirubicin 90 mg/m², cyclophosphamide 600 mg/m² for 4 cycles, followed by docetaxel 80 mg/m² for 4 cycles)
Study: 22967451
Drug: TP (docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: TP (docetaxel 75 mg/m², carboplatin AUC = 5 for 6 cycles)
Study: 16039494
Drug: Topical pilocarpine
Normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical pilocarpine 4%
Study: 12460124
Drug: Cannabis Youth
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis Youth Treatment (CYT) study
Study: 12460124
Drug: Marijuana Treatment
Normalized name: Marijuana
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marijuana Treatment Project (MTP)
Study: 9877359
Drug: Td vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Td vaccine in Grade 6 students
Study: 9877359
Drug: Td vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Td vaccine in Grade 9 students
Study: 7795925
Drug: Ondansetron (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (4 mg orally)
Study: 2612430
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A - standard brief description of upper G-I endoscopy
Study: 359245
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg codeine phosphate 4-times daily
Study: 26386383
Drug: Endoscopic repair
Normalized name: hyaluronic acid Ophthalmic Gel [Optimend Corneal Repair]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic repair of OSB using a biocellulose patch
Study: 24968955
Drug: COT1 (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: COT1 (45 hours of conventional occupational therapy)
Study: 24968955
Drug: COT2 (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: COT2 (80 hours of conventional occupational therapy)
Study: 24968955
Drug: FES +
Normalized name: Ferric Ethylenediamine Tetraacetic Acid (Ferric EDTA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FES + COT (40 hours of COT therapy + 40 hours of FES therapy)
Study: 16102611
Drug: Endovascular Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular Therapy (ET)
Study: 11957554
Drug: Daily regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily regimen (2HRZ/2HR) - 2 months of isoniazid (H), rifampicin (R) and pyrazinamide (Z), followed by 2 months of H and R
Study: 11957554
Drug: Combined regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined regimen (2HRZ/2H3R3) - 2 months of HRZ, followed by H and R given 3 times weekly for 2 months or 4 months if initial sputum specimens were culture positive
Study: 7137874
Drug: Conventional metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional metoprolol 100 mg twelve hourly
Study: 7137874
Drug: Metoprolol S.A.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol S.A. (slow release formulation) once daily
Study: 7137874
Drug: Oxprenolol S.R.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxprenolol S.R. (slow release formulation) once daily
Study: 31182369
Drug: Inhaled eluforsen
Normalized name: Eluforsen
DrugBank: Eluforsen (DB16154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled eluforsen (up to 50 mg, dosed 3 times per week for 4 weeks)
Study: 24438599
Drug: Dexmedetomidine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1.0 μg/kg intravenously for 10 minutes, maintained with 0.4 μg/kg and modulated from 0.2 to 0.7 μg/kg/hour in ICU
Study: 24438599
Drug: Propofol 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 0.1 mg/kg intravenously for 10 minutes, maintained with 1 to 2 mg/kg/hour in recovery room and ICU
Study: 23062388
Drug: Allergen immunotherapy
Normalized name: Allergen immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergen immunotherapy with higher serum level of 25(OH)D
Study: 23062388
Drug: Allergen immunotherapy
Normalized name: Allergen immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergen immunotherapy with 25(OH)D serum level higher than 30 ng/mL
Study: 17635283
Drug: Infusion group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion group (pantoprazole 80 mg i.v. bolus followed by continuous infusion of 8 mg/h for 3 days)